Aitia’s Post

In our recent webinar, Kaj Blennow, PhD, emphasized the pressing need for blood-based biomarkers to enhance the accuracy of Alzheimer's disease (AD) diagnosis and discussed the role of the ALZpath Inc. #pTau217 assay in clinical care. Learn more in our webinar: https://lnkd.in/gqp8U-ti Let's join forces to champion biomarker innovation, ensuring equitable access and transforming Alzheimer’s care globally. #ALZpath #AlzheimersAwareness #BiomarkerInnovation #HealthcareAdvancement, Andreas Jeromin

We believe that greater #innovation is needed in the development and delivery of effective models and networks for people living with a neurodegenerative disease of ageing.   Everyone facing a diagnosis should have access to reliable information and resources, specialist advice, and peer support.   Find out about 2024 funding programme: The Characterisation of Novel Biomarkers for Neurodegenerative Diseases of Ageing here: https://lnkd.in/ezc9jgiN   #innovation #ageing #healthyageing #peersupport

A rare disease is defined as affecting fewer than 1 in 2,000 people - stunting researchers' ability to understand these diseases due to the scarcity in diagnosis and limited research opportunities. CMI's model aims to change that by enabling all cancer patients regardless of where they live or have been treated in the US and Canada to share their experiences, medical histories, and biological samples with the research community across the world. Learn more about our mission at JoinCountMeIn.org. #RareDiseaseDay #CountMeIn

The NIA-AA Research Framework has refined our approach to Alzheimer's disease (AD), emphasizing biological markers over clinical symptoms. With this established framework, AD is now defined by detectable biomarkers in living patients. This essential shift allows for earlier identification of the disease through markers of beta-amyloid deposition, pathologic tau, and neurodegeneration, known collectively as the AT(N) framework. By targeting the biological underpinnings of AD, this methodology not only deepens our understanding but also enhances the precision of both research and treatment strategies, potentially halting the disease before symptoms significantly advance. 🧠How do you see this evolution influencing our strategies in combating AD? #AlzheimersResearch #BiologicalMarkers #HealthcareInnovation

This #ParkinsonsAwarenessMonth, we will raise awareness of #Parkinsons disease and, from the front lines, spotlight groundbreaking progress in PD research. Imagine a world where Parkinson's disease can be detected with high accuracy and where treatments are tailored precisely to the patient’s profile. Thanks to breakthroughs in biomarker research, that future is closer than ever. Dr. Werner Poewe explains how this isn’t just a dream - it’s happening now. Imaging advancements and a deeper understanding of subtypes of the disease are opening doors to targeted therapies and even the potential for disease #prevention. At AC Immune we’re not just watching the future of precision medicine unfold, we’re actively shaping it and #PrecisionMedicine will open up unprecedented opportunities to stop neurodegenerative diseases. Stay tuned to learn more about the latest breakthroughs as we continue to lead the charge! Watch the full AD/PD 2024 symposium on the latest advances in Parkinson’s research here: https://lnkd.in/eFX32kr9

The Clinical Laboratory Services Market is anticipated to hit a whopping USD 380.65 billion by 2029! The surge in chronic and infectious diseases, coupled with the demand for precise and early diagnosis methods, fuels this growth. Additionally, the rising burden of cancer is set to further drive the demand for clinical diagnostics. Want to dive deeper into the reports? Click here for more insights: https://lnkd.in/deYrp734 Major Players: OPKO Health, Inc. | Quest Diagonostics | Labcorp | NeoGenomics Laboratories | Myriad Genetics #Clinicallaboratory #healthcare #marketresearch #marketintelligence #mordorintelligence

The link between EBV and Alzheimer's disease is not new, but not been investigated on the epitope level. Accordingly, this paper is quite interesting to further shed light on this hardly explored link. #ebv #alzheimer

Exciting research on Alzheimer's disease (AD) from Kyu-Young Sim's team! This study revealed significant antibody differences between AD patients and controls, particularly the down-regulation of an antibody targeting an Epstein-Barr virus (EBV) epitope. This finding links EBV reactivation to increased AD risk in females. Explore the full publication to see how our peptide microarrays contributed to these crucial insights: https://lnkd.in/dHNMMk6Q #AlzheimersResearch #PeptideMicroarrays #EpitopeMapping #ScientificResearch

🌍 On the road to #RareDiseaseDay, let's shed light on the millions impacted by rare diseases, a number surpassing those affected by cancer and Alzheimer's combined. At AstraZeneca, we're diving deep into the complexities of rare disease research, embracing the challenges with innovation and resilience. 🧬 🤝 With fewer than 10% of these diseases having approved treatments, our commitment to finding solutions is more crucial than ever. By integrating insights directly from the rare disease community, we're not just conducting research; we're leading a movement towards patient-centric clinical trials and breakthroughs in healthcare. 🚀 Join us in this journey. Let's make a tangible difference together. Read more: https://lnkd.in/eeR-cjMA

September is World #Alzheimers Month There have been significant advances in Alzheimer's research - bringing hope to this highly prevalent disease. In the last few years alone, we've witnessed the approval of the first disease-modifying treatments, learned about new pathological factors affecting disease development and will soon have access to blood-based biomarker tests. This is only the start of changing the course and impact of this devastating disease. Learn more: https://lnkd.in/gHZt7_vv $INM #Awareness #Research #AlzheimersFuture